The push by Bill Gates and the WHO(World Health Organization) /PAHO(Pan American Health Organization) to introduce weight-loss drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) in low- and middle-income nations raises serious ethical, medical, and economic concerns. While obesity is a growing global health crisis, relying on pharmaceutical interventions—especially in resource-limited settings—may not be the best … Continue reading Unveiling the Weight-loss Drug Agenda: Bill Gates and WHO/PAHO’s Push for Obesity Solutions in Low- and Middle-Income Countries